This clinical trial is focused on studying treatments for Crohn’s disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study aims to evaluate the effectiveness of achieving a target of healing the intestinal wall, known as transmural healing, without the use of corticosteroids, which are a type of medication often used to reduce inflammation. The study will compare this approach to the traditional goal of achieving clinical remission, where symptoms are reduced or disappear, and biomarker remission, which involves normalizing certain blood tests.

Participants in the study will receive one or more of the following treatments: Upadacitinib (also known as ABT-494), Vedolizumab, Risankizumab (also known as BI 655066 or ABBV-066), Adalimumab (also known as ABP 501), Infliximab (also known as ABP 710), Ustekinumab (also known as Bmab 1200), Prednisone, and Budesonide. These medications are administered in various forms, such as oral tablets or intravenous infusions, and are designed to target different aspects of the immune system to reduce inflammation and promote healing. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study will last for up to 96 weeks, with participants undergoing regular assessments to monitor their health and the effectiveness of the treatment. The main goal is to determine if the new treatment approach leads to better outcomes for patients with Crohn’s disease compared to the traditional methods. Participants will be closely monitored for any side effects or complications throughout the study period.